- Home
- NSSC vs RCKT Comparison
NSSC vs RCKT Comparison
Compare NSSC & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NSSC | RCKT |
|---|---|---|
| Founded | 1969 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 534.2M |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | NSSC | RCKT |
|---|---|---|
| Price | $43.10 | $3.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 14 |
| Target Price | ★ $48.17 | $29.73 |
| AVG Volume (30 Days) | 793.5K | ★ 4.1M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $181,621,000.00 | N/A |
| Revenue This Year | $13.63 | N/A |
| Revenue Next Year | $10.05 | $51.17 |
| P/E Ratio | $57.64 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.14 | $2.19 |
| 52 Week High | $47.61 | $8.26 |
Technical Indicators
Market Signals| Indicator | NSSC | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 56.60 | 41.27 |
| Support Level | $41.75 | $2.99 |
| Resistance Level | $44.43 | $4.08 |
| Average True Range (ATR) | 1.56 | 0.35 |
| MACD | 0.20 | -0.11 |
| Stochastic Oscillator | 85.60 | 15.04 |
Price Performance
Historical ComparisonAbout NSSC NAPCO Security Technologies Inc.
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.